CA3236827A1 - Pharmaceutical compositions of humanized anti-cd40 antibodies - Google Patents
Pharmaceutical compositions of humanized anti-cd40 antibodies Download PDFInfo
- Publication number
- CA3236827A1 CA3236827A1 CA3236827A CA3236827A CA3236827A1 CA 3236827 A1 CA3236827 A1 CA 3236827A1 CA 3236827 A CA3236827 A CA 3236827A CA 3236827 A CA3236827 A CA 3236827A CA 3236827 A1 CA3236827 A1 CA 3236827A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- polysorbate
- acetate
- antibody
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276363P | 2021-11-05 | 2021-11-05 | |
| US63/276,363 | 2021-11-05 | ||
| PCT/US2022/079072 WO2023081652A1 (en) | 2021-11-05 | 2022-11-01 | Pharmaceutical compositions of humanized anti-cd40 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3236827A1 true CA3236827A1 (en) | 2023-05-11 |
Family
ID=86242030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3236827A Pending CA3236827A1 (en) | 2021-11-05 | 2022-11-01 | Pharmaceutical compositions of humanized anti-cd40 antibodies |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230279135A1 (enExample) |
| EP (2) | EP4785927A2 (enExample) |
| JP (1) | JP2024540377A (enExample) |
| KR (1) | KR20240095255A (enExample) |
| CN (1) | CN118382640A (enExample) |
| AU (1) | AU2022381078A1 (enExample) |
| CA (1) | CA3236827A1 (enExample) |
| MX (1) | MX2024005415A (enExample) |
| WO (1) | WO2023081652A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040932A1 (en) | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMP200800064B (it) * | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| HUE065915T2 (hu) | 2011-03-11 | 2024-06-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásaik |
| WO2017040932A1 (en) * | 2015-09-04 | 2017-03-09 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
-
2022
- 2022-11-01 WO PCT/US2022/079072 patent/WO2023081652A1/en not_active Ceased
- 2022-11-01 JP JP2024526890A patent/JP2024540377A/ja active Pending
- 2022-11-01 CA CA3236827A patent/CA3236827A1/en active Pending
- 2022-11-01 KR KR1020247016673A patent/KR20240095255A/ko active Pending
- 2022-11-01 MX MX2024005415A patent/MX2024005415A/es unknown
- 2022-11-01 EP EP26170924.0A patent/EP4785927A2/en active Pending
- 2022-11-01 AU AU2022381078A patent/AU2022381078A1/en active Pending
- 2022-11-01 EP EP22890984.2A patent/EP4426744A4/en not_active Withdrawn
- 2022-11-01 US US18/051,807 patent/US20230279135A1/en not_active Abandoned
- 2022-11-01 CN CN202280075264.6A patent/CN118382640A/zh active Pending
-
2025
- 2025-05-23 US US19/216,990 patent/US20250282884A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230279135A1 (en) | 2023-09-07 |
| EP4785927A2 (en) | 2026-08-05 |
| US20250282884A1 (en) | 2025-09-11 |
| KR20240095255A (ko) | 2024-06-25 |
| AU2022381078A1 (en) | 2024-05-23 |
| MX2024005415A (es) | 2024-07-30 |
| EP4426744A1 (en) | 2024-09-11 |
| EP4426744A4 (en) | 2025-10-22 |
| WO2023081652A1 (en) | 2023-05-11 |
| CN118382640A (zh) | 2024-07-23 |
| JP2024540377A (ja) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230279135A1 (en) | Pharmaceutical compositions of humanized anti-cd40 antibodies | |
| US20260139045A1 (en) | Stabilized formulations containing anti-angptl3 antibodies | |
| AU2015260758B2 (en) | Antibody formulation | |
| EP3781209B1 (en) | Viscosity reduction of highly concentrated protein formulations | |
| US20250114449A1 (en) | Stable anti-osmr antibody formulation | |
| KR102413592B1 (ko) | 약학적 제형 및 그의 제조 방법 | |
| US12234294B2 (en) | Pharmaceutical composition of a humanized anti-CD40 antibody | |
| KR20250025681A (ko) | 항-igf-1r 항체 조성물 | |
| HK40109865A (en) | Stable anti-osmr antibody formulation | |
| TWI771335B (zh) | 穩定藥學調配物 | |
| BR122024022996A2 (pt) | Formulação estável de anticorpo anti-osmr e os usos do anticorpo anti-osmr e da formulação estável do mesmo | |
| IL322811A (en) | Anti-FEL D1 antibody formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS Effective date: 20241017 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260226 |